Literature DB >> 20428950

Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis.

Myoung Hee Lee1, Jae Youn Cheong, Soon Ho Um, Yeon Seok Seo, Dong Joon Kim, Seong Gyu Hwang, Jin Mo Yang, Kwang-Hyub Han, Sung Won Cho.   

Abstract

BACKGROUND: Progressive hepatic fibrosis with development of cirrhosis is a feature of almost all chronic liver diseases. AIMS: We assessed the performance of Fibroscan in patients with chronic viral hepatitis, and in comparison with and combined with several surrogate serum markers for predicting cirrhosis.
METHODS: In this prospective multicenter cohort study, a novel panel of serum markers was constructed and serum levels of surrogate markers of liver fibrosis and Fibroscan were compared with the stage of fibrosis in the liver biopsy specimens obtained from 121 subjects with chronic viral hepatitis. Another 159 patients were enrolled to validate the diagnostic accuracy of this novel panel.
RESULTS: Multivariate analysis identified platelet count and procollagen III N-terminal peptide (PIIINP) as independent predictors of liver cirrhosis. The PP score (combining of platelet count and PIIINP) showed significantly better diagnostic accuracy (areas under the receiver operating characteristic curves, AUROC: 0.885) than that of previously reported serologic tests, including APRI, Forns fibrosis index, FIB-4 index and ELF algorithm, in the validation group (AUROC: 0.792, 0.740, 0.800, and 0.775, respectively). The AUROC of Fibroscan was 0.743 and the best performance was obtained by combining Fibroscan, platelet count and PIIINP, with an AUROC of 0.826. However, there was no significant difference among the AUROCs of Fibroscan alone, PP score, the combination of Fibroscan and PP score, and previously reported serologic tests in the estimation group.
CONCLUSIONS: Fibroscan and surrogate serum markers had similar accuracy for predicting cirrhosis, and combining Fibroscan and serum markers did not improve the accuracy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20428950     DOI: 10.1007/s10620-010-1219-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Pain experienced during percutaneous liver biopsy.

Authors:  L Castéra; I Nègre; K Samii; C Buffet
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

Review 2.  Non-invasive (and minimally invasive) diagnosis of oesophageal varices.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2008-07-26       Impact factor: 25.083

3.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

4.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

5.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

6.  Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

Authors:  C Niederau; S Lange; T Heintges; A Erhardt; M Buschkamp; D Hürter; M Nawrocki; L Kruska; F Hensel; W Petry; D Häussinger
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

7.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Authors:  Indra Neil Guha; Julie Parkes; Paul Roderick; Dipanker Chattopadhyay; Richard Cross; Scott Harris; Philip Kaye; Alastair D Burt; Steve D Ryder; Guruprasad P Aithal; Christopher P Day; William M Rosenberg
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Kazuhiro Toyoda; Hiroaki Takeoka; Shigeru Otaguro; Maki Hamada; Masayuki Murata; Yasunori Sawayama; Jun Hayashi
Journal:  Hepatol Res       Date:  2007-07-01       Impact factor: 4.288

10.  Meta-analyses of FibroTest diagnostic value in chronic liver disease.

Authors:  Thierry Poynard; Rachel Morra; Philippe Halfon; Laurent Castera; Vlad Ratziu; Françoise Imbert-Bismut; Sylvie Naveau; Dominique Thabut; Didier Lebrec; Fabien Zoulim; Marc Bourliere; Patrice Cacoub; Djamila Messous; Mona Munteanu; Victor de Ledinghen
Journal:  BMC Gastroenterol       Date:  2007-10-15       Impact factor: 3.067

View more
  17 in total

1.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 2.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 3.  Non-invasive diagnosis of advanced fibrosis and cirrhosis.

Authors:  Suraj Sharma; Korosh Khalili; Geoffrey Christopher Nguyen
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 4.  Liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfection: Diagnostic methods and clinical impact.

Authors:  Caterina Sagnelli; Salvatore Martini; Mariantonietta Pisaturo; Giuseppe Pasquale; Margherita Macera; Rosa Zampino; Nicola Coppola; Evangelista Sagnelli
Journal:  World J Hepatol       Date:  2015-10-28

5.  The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

Authors:  Mette J Nielsen; Anders F Nedergaard; Shu Sun; Sanne S Veidal; Lise Larsen; Qinlong Zheng; Charlotte Suetta; Kim Henriksen; Claus Christiansen; Morten A Karsdal; Diana J Leeming
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

Review 6.  A health technology assessment of transient elastography in adult liver disease.

Authors:  Rodney Steadman; Robert P Myers; Laura Leggett; Diane Lorenzetti; Tom Noseworthy; Sarah Rose; Lloyd Sutherland; Fiona Clement
Journal:  Can J Gastroenterol       Date:  2013-03       Impact factor: 3.522

Review 7.  A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

Authors:  Waqar Ahmad; Bushra Ijaz; Sana Gull; Sultan Asad; Saba Khaliq; Shah Jahan; Muhammad T Sarwar; Humera Kausar; Aleena Sumrin; Imran Shahid; Sajida Hassan
Journal:  Virol J       Date:  2011-02-08       Impact factor: 4.099

8.  Spectral CT: preliminary studies in the liver cirrhosis.

Authors:  Peijie Lv; Xiaozhu Lin; Jianbo Gao; Kemin Chen
Journal:  Korean J Radiol       Date:  2012-06-18       Impact factor: 3.500

9.  Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.

Authors:  Beom Kyung Kim; Hyon Suk Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Chae Yoon Chon; Young Nyun Park; Kwang-Hyub Han; Seung Up Kim
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography.

Authors:  Kristin Wahl; William Rosenberg; Bernhard Vaske; Michael P Manns; Klaus Schulze-Osthoff; Matthias J Bahr; Heike Bantel
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.